(Q44286199)

1 December 2017

title

Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy (English)

1 reference

1 December 2017

main subject

peginterferon alfa-2a

1 reference

4

K Rajender Reddy

1 reference

1 December 2017

2

William Cassidy

1 reference

1 December 2017

Shengyuan Luo

1

1 reference

1 December 2017

Lennox Jeffers

series ordinal

3

1 reference

1 December 2017

Christine Bruno

series ordinal

5

1 reference

1 December 2017

Charles D Howell

series ordinal

6

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Clinical Gastroenterology and Hepatology

1 December 2017

published in

1 reference

1 December 2017

volume

3

1 reference

1 December 2017

issue

5

1 reference

1 December 2017

page(s)

499-506

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Risk factors for the rising rates of primary liver cancer in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

How cells respond to interferons

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Activity and tolerance of a continuous subcutaneous infusion of interferon-alpha2b in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to alpha-interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900615-9

7 January 2021

10.1016/S1542-3565(04)00615-9

Identifiers

DOI

1 reference

1 December 2017

1 reference